SMAD4 and neoplasm: The second most frequently mutated gene was TP53 (13/21 tumor patients; 61.9%), followed by CDKN2A (5/21; 23.8%), SMAD4 (2/21; 9.5%), and GNAS and BRAF (both 1/21; 4.8%, Table S2).